Survival extrapolation models’ impact on cost-effectiveness assessments for reimbursement of oncolytics

    Research output: ThesisThesis fully internal (DIV)

    126 Downloads (Pure)


    The burden of cancer is rapidly growing worldwide, posing a challenge for the affordability and access to our healthcare systems. To ensure the limited resources are spent in the most optimal way, many countries perform a Health Technology Assessment (HTA), before reimbursing new oncology treatments. At the time of HTA, data from clinical trials is often incomplete or “immature”, especially for innovative oncology treatments for which regulatory bodies provide accelerated or conditional approval. Consequently, a substantial part of the trial data needs to be extrapolated and the reliability of HTA conclusions decreases.

    In this thesis, the outcomes of different survival extrapolation models are compared for oncology trial data with different levels of data maturity. The thesis aims to explore the impact thereof on the results of cost-effectiveness modelling and decision-making for reimbursement purposes, taking levels of maturity and the existence of a group of long-term survivors explicitly into account.
    Original languageEnglish
    QualificationDoctor of Philosophy
    Awarding Institution
    • University of Groningen
    • Buskens, Erik, Supervisor
    • Postma, Maarten, Supervisor
    Award date27-Mar-2024
    Place of Publication[Groningen]
    Publication statusPublished - 2024

    Cite this